A Phase 1/2 interventional study of Luliconazole Solution, 10% in Onychomycosis, sponsored by Topica Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-11-26.
Sponsored by Topica Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Onychomycosis with a site in United States — 3 open to participants now, 7 under way, 1 of them phase 3. Onychomycosis · United States.
Among the 77 studies in Onychomycosis with a site in United States, this one is the 56th largest by enrollment of the 75 interventional ones that give a count, is one of 6 that started in 2010, is the only one in phase 1/2, and was the 28th registered.
158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.
Browse Onychomycosis studies →3 of the 77 studies in Onychomycosis with a site in United States are open now. Recruiting first, the newest first:
Nail Genesis LLC · Sites in United States
Ages 18–65
Next Science TM · Sites in United States
Ages 18+
SATO Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 27 · Phase 3 17 · Phase 4 5
First in 2002; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 60 across 143 interventional studies indexed under Onychomycosis.
Median enrollment 50 across the 75 interventional studies, 33 across the 2 observational. Of the 62 that completed or were terminated, 23 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 77 have an industry lead sponsor. The 10 most frequent:
Topica Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.
Topica Pharmaceuticals has 2 studies filed under Onychomycosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Onychomycosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07756671The University of Texas Health Science Center, HoustonPhotodynamic Therapy For Onychomycosis | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 77 studies in Onychomycosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the safety, tolerability, systemic exposure and pharmacokinetics of luliconazole after repeat daily topical application of Luliconazole Solution, 10% in a maximal use setting in adults with distal subungual onychomycosis of the toenails.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Luliconazole Solution, 10%
28 days of daily application
PK parameters (AUC, Cmax, Tmax, t1/2) will be measured at days 1 (Baseline), 9, 15 and 29. Safety assessments include monitoring of adverse events, local site tolerability, ECG monitoring, and changes in laboratory values and vital signs.
Time frame: March 2011
Evaluation of linear toenail growth.
Time frame: March 2011
The record gives a start of Dec 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Topica Pharmaceuticals